优化[212Pb]Pb-AB001放射配体治疗在PSMA阳性皮下前列腺癌异种移植瘤中的给药方案
该临床前研究在PC-3 PIP皮下前列腺癌异种移植小鼠中比较[212Pb]Pb-AB001不同给药方案(单次、Q7d、Q14d、Q3d)及累积活度对疗效与毒性的影响。结果显示多周期Q7d方案肿瘤控制最佳,0.4 MBq×4周期Q7d使中位生存延长至116天、33%完全缓解,且未观察到全身毒性。
要点
- Q7d方案肿瘤控制优于Q14d和Q3d方案
- 0.4 MBq×4周期Q7d中位生存116天,33%完全缓解
- 研究活度范围内未观察到全身毒性
核心结论
- [212Pb]Pb-AB001的疗效取决于周期数、给药间隔和每周期活度,多周期方案增强肿瘤控制且无毒性。
研究设计与样本
- 雄性无胸腺裸鼠皮下接种PC-3 PIP异种移植瘤,接受累积活度0.8 MBq的单次或Q7d/Q14d多周期[212Pb]Pb-AB001治疗。
- 另两项治疗研究评估0.4 MBq Q7d或Q3d方案,累积活度最高达1.6 MBq。
- 治疗后1周和2周行[18F]PSMA-1007 PET/CT显像,评估肿瘤生长、生存、毒性、放射性配体摄取及组织病理。
主要发现
- 所有方案均较对照组延缓肿瘤生长并延长生存。
- Q7d方案肿瘤控制优于Q14d和Q3d方案。
- 治疗后7天SUVmean和SUVmax较基线显著升高。
- 累积0.8 MBq组中,4×0.2 MBq Q7d方案肿瘤控制最佳,中位生存67天。
- 每周期活度增至0.4 MBq并延长至4周期Q7d,中位生存进一步延长至116天,33%完全缓解。
关键数值与推荐
- 累积活度0.8 MBq时,4×0.2 MBq Q7d组中位生存67天,为各组最佳肿瘤控制。
- 0.4 MBq×4周期Q7d方案中位生存116天,完全缓解率33%。
- Q7d方案1-4次注射间肿瘤对[212Pb]Pb-AB001的摄取保持一致。
- 研究活度范围内未观察到全身毒性。
临床怎么用
- 临床前结果支持在[212Pb]Pb-PSMA治疗临床方案中优先考虑Q7d多周期给药策略。
- 每周期活度与周期数的优化可能进一步提升疗效,需临床转化验证。
局限性
- 本研究为PC-3 PIP皮下异种移植瘤临床前模型,结果外推至临床需谨慎。
- 研究未报告长期毒性及迟发效应数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Radiopharmaceutical therapies are typically administered in multiple cycles to improve tolerability, but optimal scheduling remains undefined. Targeted α-therapy with [212Pb]Pb-AB001, a prostate-specific membrane antigen (PSMA)-targeting radioligand, is a promising approach for metastatic prostate cancer. This preclinical study evaluated how treatment schedules and cumulative activities affect therapeutic efficacy and toxicity. Methods: Male athymic nude mice bearing subcutaneous PC-3 PIP xenografts received a cumulative activity of 0.8 MBq of [212Pb]Pb-AB001 as a single or as multiple injections at 7-d intervals (Q7d) or 14-d intervals (Q14d). [18F]PSMA-1007 PET/CT imaging was performed at 1 and 2 wk after treatment. Two additional therapy studies evaluated 0.4 MBq Q7d or every third day (Q3d), with cumulative activities of up to 1.6 MBq. Tumor growth, survival, toxicity, radioligand uptake, and histopathology were evaluated. Results: All regimens delayed tumor growth and prolonged survival compared with the controls. Tumor control was improved with the Q7d regimen compared with the Q14d and Q3d regimens. SUVmean and SUVmax increased significantly 7 d after treatment compared with baseline. Among mice receiving 0.8 MBq cumulatively, the group receiving 4 × 0.2 MBq Q7d showed the best tumor control (median survival, 67 d). Increasing per-cycle activity to 0.4 MBq and extending to 4 cycles Q7d further prolonged median survival to 116 d, with 33% complete responses. Tumor uptake of [212Pb]Pb-AB001 remained consistent across 1-4 injections Q7d. Repeated treatment induced progressive tumor necrosis and edema and reduced PSMA and vascular endothelial growth factor staining. No systemic toxicity was observed at studied activities. Conclusion: The efficacy of [212Pb]Pb-AB001 radiopharmaceutical therapy depended on cycle number, interval, and per-cycle activity. Multicycle regimens enhanced tumor control without toxicity, supporting schedule optimization in clinical protocols for [212Pb]Pb-PSMA therapy.
引用
- Høyvik AJK, Stenberg VY, Liukaityte R, et al. Optimizing [212Pb]Pb-AB001 Radiopharmaceutical Therapy Schedules in PSMA-Positive Subcutaneous Prostate Cancer Xenografts. J Nucl Med. 2025. PMID: 41043994. doi:10.2967/jnumed.125.270444
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。